ZANIDATAMAB: payments to doctors
Payments that named ZANIDATAMAB as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $102K
- Providers
- 21
- Transactions
- 89
- Average per transaction
- $1,145
The per-transaction average — $1,145 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 21 providers the average total is $4,853, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| JAZZ Pharmaceuticals Inc. | $54,501 | 53.5% |
| Jazz Pharmaceuticals Inc. | $47,410 | 46.5% |